Fc fusion as a platform technology: potential for modulating immunogenicity. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Levin, Ditza; Golding, Basil; Strome, Scott E.; Sauna, Zuben E.
• Is Part Of: Trends in biotechnology. Volume 33:Issue 1(2015)
• Page Start: 27
• Page End: 34
• Publication Date: 2015-01
• Subjects: Biotechnology -- Periodicals; Biochemical engineering -- Periodicals; Genetic engineering -- Periodicals; Industrial microbiology -- Periodicals; 660.605
• DOI: 10.1016/j.tibtech.2014.11.001
• Languages: English
• ISSNs: 0167-7799

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Fc fusion, a platform technology, is used to extend the half-life of protein drugs.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">There has recently been considerable progress in understanding Fc immunobiology.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">The findings suggest a rationale for engineering the Fc in fusion therapeutics.</p> </list-item> </list> </p> </sec> </abstract>